# A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer

> **NCT02898077** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 440 (actual)

## Conditions studied

- Gastroesophageal Junction Adenocarcinoma
- Gastric Adenocarcinoma

## Interventions

- **DRUG:** Ramucirumab
- **DRUG:** Paclitaxel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02898077
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-02
- **Primary completion:** 2020-06-30
- **Final completion:** 2021-04-12
- **Target enrollment:** 440 (ACTUAL)
- **Last updated:** 2022-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02898077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02898077, "A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02898077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*